

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

APPROVAL FOR CLINICAL TRIAL OF GROUP'S PRODUCT UBT38006 INJECTION

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the application for the clinical trial of UBT38006 Injection, a Class 1 innovative drug self-developed by The United Bio-Technology (Hengqing) Co., Ltd., a wholly-owned subsidiary of the Company, was approved by China National Medical Products Administration with reference number CXSL2600257.

UBT38006 Injection is a long-acting weekly insulin product with a novel molecular structure. The drug exerts its hypoglycemic pharmacological effect by specifically binding to human insulin receptors. Compared with existing insulin products, UBT38006's most notable advantage lies in its unique molecular design, which enables reversible binding to human albumin, significantly prolonging the drug's half-life. Based on preclinical in vivo animal data, it is projected to support a once-weekly dosing regimen in humans. The development of UBT38006 is expected to substantially improve medication adherence in diabetic patients, reduce the treatment burden associated with frequent injections, and enhance patients' quality of life.

This approval marks another significant innovative achievement for the Company in the field of diabetes treatment. Moving forward, the Company will continue to advance the research and development of new products, strengthen its competitiveness and innovation in the biopharmaceutical industry, and focus on chronic disease treatment by delivering higher-quality products and a robust pipeline to serve clinical practice and benefit patients, which is expected to generate greater value for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 7 May 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.